Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood‐Onset Proliferative Lupus Nephritis

作者：Kelly Rouster‐Stevens, William Daniel Soulsby, Rebecca E. Sadun, Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Working Group, Meredith Riebschleger, Christine Wang, Maria Pereira, Scott E. Wenderfer, Kristen Miller, Emily Hause, Jennifer C. Cooper, Eveline Y. Wu, Nicole Ling, Laura Pyle, Joyce Hui‐Yuen, Laura B. Lewandowski, Christine Bacha, Marinka Twilt, Stacey P. Ardoin, Julia Shalen, Aliese Sarkissian, Wenru Zhou · 发表于：UNC Libraries · 年份：2024 · DOI：10.17615/v1nc-ge85 · 被引用次数：4 · 研究领域：Systemic Lupus Erythematosus Research、Pregnancy and Medication Impact、Liver Diseases and Immunity

OBJECTIVE: We compared clinical characteristics and renal response in patients with childhood-onset proliferative lupus nephritis (LN) treated with the EuroLupus versus National Institutes of Health (NIH) cyclophosphamide (CYC) regimen. METHODS: A retrospective cohort study was conducted at 11 pediatric centers in North America that reported using both CYC regimens. Data were extracted from the electronic medical record at baseline and 3, 6, and 12 months after treatment initiation with CYC. To evaluate the adjusted association between CYC regimen (EuroLupus vs NIH) and renal response over time, generalized estimating equations with a logit link were used. An interaction between time and CYC regimen was included, and a contrast between CYC regimens at 12 months was used to evaluate the primary outcome. RESULTS: One hundred forty-five patients (58 EuroLupus, 87 NIH) were included. EuroLupus patients were on average older at the start of current CYC therapy, had longer disease duration, and more commonly had relapsed or refractory LN compared with the NIH group. After multivariable adjustment, there was no significant association between CYC regimen and achieving complete renal response at 12 months (odds ratio [OR] of response for the EuroLupus regimen, reference NIH regimen: 0.76; 95% confidence interval [CI] 0.29-1.98). There was also no significant association between CYC regimen and achieving at least a partial renal response at 12 months (OR 1.35, 95% CI 0.57-3.19). CONCL...